

REFERENCES

- Krebs TS, Johansen PØ: Over 30 million psychedelic users in the United States [version 1; referees: 2 approved]. *F1000 Res* 2: 98, 2013.
- Substance Abuse and Mental Health Services Administration: Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future national survey results on drug use, 1975-2010. Volume I: secondary school students. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2011.
- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future national survey results on drug use, 1975-2010. Volume II: college students and adults ages 19-50. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2011.
- Milroy CM: "Ecstasy" associated deaths: what is a fatal concentration? Analysis of a case series. *Forensic Sci Med Pathol* 7: 248, 2011. [PMID: 21264549]
- Hill SL, Thomas SH: Clinical toxicology of newer recreational drugs. *Clin Toxicol (Phila)* 49: 705, 2011. [PMID: 21970769]
- Nichols DE, Johnson MW, Nichols CD: Psychedelics as medicines: an emerging new paradigm. *Clin Pharmacol Ther* 101: 209, 2017. [PMID: 28019026]
- Peet M, Peters S: Drug-induced mania. *Drug Saf* 12: 146, 1995. [PMID: 7766338]
- Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M: Adulterants in illicit drugs: a review of empirical evidence. *Drug Test Anal* 3: 89, 2011. [PMID: 21322119]
- Tanner-Smith EE: Pharmacological content of tablets sold as "ecstasy": results from an online testing service. *Drug Alcohol Depend* 83: 247, 2006. [PMID: 16364567]
- Mathias S, Lubman DI, Hides L: Substance-induced psychosis: a diagnostic conundrum. *J Clin Psychiatry* 69: 358, 2008. [PMID: 18278990]
- Caton CL, Drake RE, Hasin DS, et al: Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. *Arch Gen Psychiatry* 62: 137, 2005. [PMID: 15699290]
- Goldfrank LR, Hoffman RS: The cardiovascular effects of cocaine. *Ann Emerg Med* 20: 165, 1991. [PMID: 1996800]
- Grunau BE, Wiens MO, Brubacher JR: Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. *CJEM* 12: 435, 2010. [PMID: 20880437]
- Gable RS: Comparison of acute lethal toxicity of commonly abused psychoactive substances. *Addiction* 99: 686, 2004. [PMID: 15139867]
- Abraham HD, Aldridge AM, Gogia P: The psychopharmacology of hallucinogens. *Neuropsychopharmacology* 14: 285, 1996. [PMID: 8924196]
- Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A: The pharmacology of lysergic acid diethylamide: a review. *CNS Neurosci Ther* 14: 295, 2008. [PMID: 19040555]
- Blaho K, Merigian K, Winbery S, Geraci SA, Smarrt C: Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication. *Am J Ther* 4: 211, 1997. [PMID: 10423613]
- Berrens Z, Lammers J, White C: Rhabdomyolysis after LSD ingestion. *Psychosomatics* 51: 356.e3, 2010. [PMID: 20587768]
- Klock JC, Boerner U, Becker CE: Coma, hyperthermia, and bleeding associated with massive LSD overdose, a report of eight cases. *Clin Toxicol* 8: 191, 1975. [PMID: 1149410]
- Raval MV, Gaba RC, Brown K, et al: Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy. *J Vasc Interv Radiol* 19: 1227, 2008. [PMID: 18656018]
- Halpern JH, Pope HG Jr: Hallucinogen persisting perception disorder: what do we know after 50 years? *Drug Alcohol Depend* 69: 109, 2003. [PMID: 12609692]
- Nikolaou P, Papoutsis I, Stefanidou M, et al: 2C-I-NBOMe, an "N-bomb" that kills with "smiles." Toxicological and legislative aspects. *Drug Chem Toxicol* 38: 113, 2015. [PMID: 24785196]
- Tebo C, Mazer-Amirshahi M, DeGeorge L, et al: Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents? *Am J Emerg Med* Epub ahead of print, 24 Dec 2018. DOI 10.1016/j.ajem.2018.12.044.
- Barbee G, Berry-Caban C, Barry J, Borys D, Ward J, Salyer S: Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006. *J Med Toxicol* 5: 59, 2009. [PMID: 19415588]
- Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX: Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. *Psychopharmacology (Berl)* 172: 145, 2004. [PMID: 14615876]
- Bickel M, Ditting T, Watz H, et al: Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after "magic mushroom" abuse. *Eur J Emerg Med* 12: 306, 2005. [PMID: 16276262]
- Frank H, Zilker T, Kirchmair M, et al: Acute renal failure by ingestion of *Cortinarius* species confounded with psychoactive mushrooms: a case series and literature survey. *Clin Nephrol* 71: 557, 2009. [PMID: 19473617]
- Halpern JH: Hallucinogens and dissociative agents naturally growing in the United States. *Pharmacol Ther* 102: 131, 2004. [PMID: 15163594]
- Bronstein AC, Spyker DA, Cantilena LR Jr, et al: 2007 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th annual report. *Clin Toxicol (Phila)* 46: 927, 2008. [PMID: 19065310]
- Carstairs SD, Cantrell FL: Peyote and mescaline exposures: a 12-year review of a statewide poison center database. *Clin Toxicol (Phila)* 48: 350, 2010. [PMID: 20170392]
- CDC: Ecstasy overdoses at a New Year's Eve rave—Los Angeles, California, 2010. *MMWR Morb Mortal Wkly Rep* 59: 677, 2010. [PMID: 20535091]
- Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F: Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. *Mol Neurobiol* 39: 210, 2009. [PMID: 19373443]
- Jansen KL, Theron L: Ecstasy (MDMA), methamphetamine, and date rape (drug-facilitated sexual assault): a consideration of the issues. *J Psychoactive Drugs* 38: 1, 2006. [PMID: 16681170]
- Kaye S, Darke S, Dufloy J: Methylenedioxymethamphetamine (MDMA)-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. *Drug Alcohol Depend* 104: 254, 2009. [PMID: 19604654]
- Shenouda SK, Carvalho F, Varner KJ: The cardiovascular and cardiac actions of ecstasy and its metabolites. *Curr Pharm Biotechnol* 11: 470, 2010. [PMID: 20420571]
- Sarkar S, Schmued L: Neurotoxicity of ecstasy (MDMA): an overview. *Curr Pharm Biotechnol* 11: 460, 2010. [PMID: 20420572]
- Chang SH, Lai TI, Chen WJ, Fang CC: MDMA-induced acute pulmonary edema in a patient without other organ dysfunction. *Am J Emerg Med* 24: 734, 2006. [PMID: 16984847]
- Campbell GA, Rosner MH: The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. *Clin J Am Soc Nephrol* 3: 1852, 2008. [PMID: 18684895]
- Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR: Patterns of ecstasy-associated hyponatremia in California. *Ann Emerg Med* 49: 164, 2007. [PMID: 17084942]
- Patel MM, Belson MG, Longwater AB, Olson KR, Miller MA: Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. *J Emerg Med* 29: 451, 2005. [PMID: 16243206]
- Ben-Abraham R, Szold O, Rudick V, Weinbroum AA: "Ecstasy" intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. *Eur J Emerg Med* 10: 309, 2003. [PMID: 14676510]
- Turillazzi E, Riezzo I, Neri M, Bello S, Fineschi V: MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings. *Curr Pharm Biotechnol* 11: 500, 2010.
- Oesterheld JR, Armstrong SC, Cozza KL: Ecstasy: pharmacodynamic and pharmacokinetic interactions. *Psychosomatics* 45: 84, 2004. [PMID: 14709765]
- Kahn DE, Ferraro N, Benveniste RJ: Three cases of primary intracranial hemorrhage associated with "Molly," a purified form of 3,4-methylenedioxymethamphetamine (MDMA). *J Neurol Sci* 323: 257, 2012. [PMID: 22998806]
- McCann UD, Szabo Z, Scheffel U, et al: Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. *Lancet* 352: 1433, 1998. [PMID: 9807990]
- Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin D, Pope HG Jr: Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. *Addiction* 106: 777, 2011. [PMID: 21205042]
- Hall AP, Henry JA: Acute toxic effects of "Ecstasy" (MDMA) and related compounds: overview of pathophysiology and clinical management. *Br J Anaesth* 96: 678, 2006. [PMID: 16595612]
- Bordo DJ, Dorfman MA: Ecstasy overdose: rapid cooling leads to successful outcome. *Am J Emerg Med* 22: 326, 2004. [PMID: 15258886]
- Mugele J, Nanagas KA, Tormoehlen LM: Serotonin syndrome associated with MDPV use: a case report. *Ann Emerg Med* 60: 100, 2012. [PMID: 22237165]
- Weinstein AM, Rosca P, Fattore L, London ED: Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. *Front Psychiatry* 8: 156, 2017. [PMID: 28878698]
- Karch SB: Cathinone neurotoxicity (the "3Ms"). *Curr Neuropharmacol* 13: 21, 2015. [PMID: 26074741]
- Prosser JM, Nelson LS: The toxicology of bath salts: a review of synthetic cathinones. *J Med Toxicol* 8: 33, 2012. [PMID: 22108839]
- Penders TM, Gestring RE, Vilensky DA: Excited delirium following use of synthetic cathinones (bath salts). *Gen Hosp Psychiatry* 34: 647, 2012. [PMID: 22898445]
- Hoiseth G, Hjelmeland K, Bachs L: [Phencyclidine—angel dust]. *Tidsskr Nor Laegeforen* 125: 2775, 2005. [PMID: 16244678]
- O'Shea B: Phencyclidine, ketamine, and khat phencyclidine (PCP, DOA, 'angel dust', 'crystal', 'hog'). *Ir Med J* 93: 185, 2005. [PMID: 11105446]
- McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA: Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. *Ann Emerg Med* 10: 237, 1981.
- McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA: Acute phencyclidine intoxication: clinical patterns, complications, and treatment. *Ann Emerg Med* 10: 290, 1981.
- Milhorn HT Jr: Diagnosis and management of phencyclidine intoxication. *Am Fam Physician* 43: 1293, 1991. [PMID: 2008817]
- Eastman JW, Cohen SN: Hypertensive crisis and death associated with phencyclidine poisoning. *JAMA* 231: 1270, 1975. [PMID: 1172955]
- Stein GY, Fradin Z, Ori Y, Singer P, Korobko Y, Zeidman A: Phencyclidine-induced multi-organ failure. *Is Med Assoc J* 7: 535, 2005. [PMID: 16106785]
- Simpson GM, Khajawall AM, Alatorre E, Staples FR: Urinary phencyclidine excretion in chronic abusers. *J Toxicol Clin Toxicol* 19: 1051, 1982. [PMID: 7184997]
- Devane WA, Hanus L, Breuer A, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258: 1946, 1992. [PMID: 1470919]

64. Sinclair CF, Foushee HR, Pevear JS 3rd, Scarinci IC, Carroll WR: Patterns of blunt use among rural young adult African-American men. *Am J Prev Med* 42: 61, 2012. [PMID: 22176848]
65. Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry* 28: 849, 2004. [PMID: 15363608]
66. Aryana A, Williams MA: Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? *Int J Cardiol* 118: 141, 2007. [PMID: 17005273]
67. Pratap B, Korniyenko A: Toxic effects of marijuana on the cardiovascular system. *Cardiovasc Toxicol* 12: 143, 2012. [PMID: 22194141]
68. Maxwell JC, Mendelson B: What do we know about the impact of the laws related to marijuana? *J Addict Med* 10: 3, 2016. [PMID: 26818826]
69. Wang GS, Le Lait M, Deakney SJ, Bronstein AC, Bajaj L, Roosevelt G: Unintentional pediatric exposures to marijuana in Colorado, 2009-2015. *JAMA Pediatr* 170: e160971, 2016. [PMID: 27454910]
70. McGuinness TM: Update on marijuana. *J Psychosoc Nurs Ment Health Serv* 47: 19, 2009. [PMID: 19835316]
71. Reece AS: Chronic toxicology of cannabis. *Clin Toxicol (Phila)* 47: 517, 2009. [PMID: 19586351]
72. Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ: Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognized manifestation of chronic cannabis abuse. *World J Gastroenterol* 15: 1264, 2009. [PMID: 19291829]
73. Wallace EA, Andrews SE, Garmany CL, Jelley MJ: Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. *South Med J* 104: 659, 2011. [PMID: 21886087]
74. Dezieck L, Hafez Z, Conicella A, et al: Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. *Clin Toxicol (Phila)* 55: 908, 2017. [PMID: 28494183]
75. Lapoint J, Meyer S, Yu CK, et al: Cannabinoid hyperemesis syndrome: public health implications and a novel model treatment guideline. *West J Emerg Med* 19: 380, 2018. [PMID: 29560069]
76. Dackis CA, Pottash AL, Annitto W, Gold MS: Persistence of urinary marijuana levels after supervised abstinence. *Am J Psychiatry* 139: 1196, 1982. [PMID: 6287871]
77. Atwood BK, Huffman J, Straiker A, Mackie K: JWH018, a common constituent of "spice" herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. *Br J Pharmacol* 160: 585, 2010. [PMID: 20100276]
78. Dresen S, Ferreiros N, Putz M, et al: Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. *J Mass Spectrom* 45: 1186, 2010. [PMID: 20857386]
79. Rosenbaum CD, Carreiro SP, Babu KM: Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, *Salvia divinorum*, methoxetamine, and piperazines. *J Med Toxicol* 8: 15, 2012. [PMID: 22271566]
80. Hudson S, Ramsey J: The emergence and analysis of synthetic cannabinoids. *Drug Test Anal* 3: 466, 2011. [PMID: 21337724]
81. Wells DL, Ott CA: The "new" marijuana. *Ann Pharmacother* 45: 414, 2011. [PMID: 21325097]
82. <https://www.cdc.gov/nceh/hsb/chemicals/sc/default.html> (Centers for Disease Control and Prevention: Synthetic cannabinoids: what are they? What are their effects?) Accessed March 16, 2019.
83. Every-Palmer S: Synthetic cannabinoid JWH-018 and psychosis: an exploratory study. *Drug Alcohol Depend* 117: 152, 2011. [PMID: 21316162]
84. Corazza O, Schifano F, Farre M, et al: Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. *Curr Clin Pharmacol* 6: 125, 2011. [PMID: 21592070]
85. Corazza O, Schifano F, Farre M, et al: Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. *Curr Clin Pharmacol* 6: 125, 2011. [PMID: 21592070]
86. Wood DM, Looker JJ, Shaikh L, et al: Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. *J Med Toxicol* 5: 226, 2009. [PMID: 19876858]
87. Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M: A fatal poisoning involving Bromo-Dragonfly. *Forensic Sci Int* 183: 91, 2009. [PMID: 19091499]
88. Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P: The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. *Clin Toxicol (Phila)* 49: 131, 2011. [PMID: 21495881]
89. Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI: Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and 1-benzylpiperazine (BZP). *J Med Toxicol* 4: 254, 2008.
90. Halpern JH, Pope HG Jr: Hallucinogens on the Internet: a vast new source of underground drug information. *Am J Psychiatry* 158: 481, 2001. [PMID: 11229993]
91. Babu KM, McCurdy CR, Boyer EW: Opioid receptors and legal highs: *Salvia divinorum* and kratom. *Clin Toxicol (Phila)* 46: 146, 2008. [PMID: 18259963]
92. Prisinzano TE: Psychopharmacology of the hallucinogenic sage *Salvia divinorum*. *Life Sci* 78: 527, 2005. [PMID: 16213533]
93. Dalgarno P: Subjective effects of *Salvia divinorum*. *J Psychoactive Drugs* 39: 143, 2007. [PMID: 17703708]
94. Vohra R, Seefeld A, Cantrell FL, Clark RF: *Salvia divinorum*: exposures reported to a statewide poison control system over 10 years. *J Emerg Med* 40: 643, 2011. [PMID: 19765944]
95. Hitt M, Ettinger DD: Toad toxicity. *N Engl J Med* 314: 1517, 1986. [PMID: 3702971]
96. Gowda RM, Cohen RA, Khan IA: Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. *Heart* 89: e14, 2003. [PMID: 12639891]
97. Kostakis C, Byard RW: Sudden death associated with intravenous injection of toad extract. *Forensic Sci Int* 188: e1, 2009. [PMID: 19303230]
98. Kuo HY, Hsu CW, Chen JH, Wu YL, Shen YS: Life-threatening episode after ingestion of toad eggs: a case report with literature review. *BMJ Case Rep* pii: bcr11.2008.1241, 2009. [PMID: 21686394]
99. Brubacher JR, Ravikumar PR, Bania T, Heller MB, Hoffman RS: Treatment of toad venom poisoning with digoxin-specific Fab fragments. *Chest* 110: 1282, 1996. [PMID: 8915235]
100. Brubacher JR, Lachman D, Ravikumar PR, Hoffman RS: Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. *Toxicol* 37: 931, 1999. [PMID: 10340832]
101. Demetriades AK, Wallman PD, McGuinness A, Gavalas MC: Low cost, high risk: accidental nutmeg intoxication. *Emerg Med J* 22: 223, 2005. [PMID: 15735280]
102. Ehrenpreis JE, DesLauriers C, Lank P, et al: Nutmeg poisonings: a retrospective review of 10 years experience from the Illinois poison center, 2001-2011. *J Med Toxicol* 10: 148, 2014. [PMID: 24452991]
103. Vearrier D, Greenberg MI: Anticholinergic delirium following *Datura stramonium* ingestion: implications for the Internet age. *J Emerg Trauma Shock* 3: 303, 2010. [PMID: 20930988]
104. Glatstein MM, Alabdulrazzaq F, Garcia-Bournissen F, Scolnik D: Use of physostigmine for hallucinogenic plant poisoning in a teenager: case report and review of the literature. *Am J Ther* 19: 384, 2012. [PMID: 20861718]
105. Wolff K, Winstock AR: Ketamine: from medicine to misuse. *CNS Drugs* 20: 199, 2006. [PMID: 16529526]
106. Jansen KL: A review of the nonmedical use of ketamine: use, users and consequences. *J Psychoactive Drugs* 32: 419, 2000. [PMID: 11210204]
107. Weiner AL, Vieira L, McKay CA, Bayer MJ: Ketamine abusers presenting to the emergency department: a case series. *J Emerg Med* 18: 447, 2000. [PMID: 10802423]
108. Bokor G, Anderson PD: Ketamine: an update on its abuse. *J Pharm Practice* 27: 582, 2014. [PMID: 24651639]
109. Boyer EW: Dextromethorphan abuse. *Pediatr Emerg Care* 20: 858, 2004. [PMID: 15572980]
110. Wilson MD, Ferguson RW, Mazer ME, Litovitz TL: Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000-2010. *Clin Toxicol (Phila)* 49: 409, 2011. [PMID: 21740139]